Your browser doesn't support javascript.
loading
Process description of developing HIV prevention monitoring indicators for a province-wide pre-exposure prophylaxis (PrEP) program in British Columbia, Canada.
Munasinghe, Lalani L; Toy, Junine; Lepik, Katherine J; Moore, David M; Hull, Mark; Bacani, Nic; Sereda, Paul; Barrios, Rolando; Montaner, Julio S G; Lima, Viviane D.
Afiliação
  • Munasinghe LL; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
  • Toy J; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
  • Lepik KJ; St. Paul's Hospital Ambulatory Pharmacy, St. Paul's Hospital, Vancouver, British Columbia, Canada.
  • Moore DM; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
  • Hull M; St. Paul's Hospital Ambulatory Pharmacy, St. Paul's Hospital, Vancouver, British Columbia, Canada.
  • Bacani N; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
  • Sereda P; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Barrios R; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
  • Montaner JSG; Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Lima VD; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
PLoS One ; 18(3): e0283025, 2023.
Article em En | MEDLINE | ID: mdl-36920956
ABSTRACT
In 2018, the pre-exposure prophylaxis (PrEP) program was initiated in British Columbia (BC), Canada, providing PrEP at no cost to qualifying residents. This observational study discussed the steps to develop key evidence-based monitoring indicators and their calculation using real-time data. The indicators were conceptualized, developed, assessed and approved by the Technical Monitoring Committee of representatives from five health authority regions in BC, the BC Ministry of Health, the BC Centre for Disease Control, and the BC Centre for Excellence in HIV/AIDS. Indicator development followed the steps adopted from the United States Centers for Disease Control and Prevention framework for program evaluation in public health. The assessment involved eight selection criteria data quality, indicator validity, existing scientific evidence, indicator informativeness, indicator computing feasibility, clients' confidentiality maintenance capacity, indicator accuracy, and administrative considerations. Clients' data from the provincial-wide PrEP program (January 2018-December 2020) shows the indicators' calculation. The finalized 14 indicators included gender, age, health authority, new clients enrolled by provider type and by the health authority, new clients dispensed PrEP, clients per provider, key qualifying HIV risk factor(s), client status, PrEP usage type, PrEP quantity dispensed, syphilis and HIV testing and incident cases, and adverse drug reaction events. Cumulative clients' data (n = 6966; 99% cis-gender males) identified an increased new client enrollment and an unexpected drop during the COVID-19 pandemic. About 80% dispensed PrEP from the Vancouver Coastal health authority. The HIV incidence risk index for men who have sex with men score ≥10 was the most common qualifying risk factor. The framework we developed integrating indicators was applied to monitor our PrEP program, which could help reduce the public health impact of HIV.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Infecções por HIV / Síndrome da Imunodeficiência Adquirida / Fármacos Anti-HIV / Profilaxia Pré-Exposição / Minorias Sexuais e de Gênero / COVID-19 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: America do norte Idioma: En Revista: PLoS One Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 / 4_TD Base de dados: MEDLINE Assunto principal: Infecções por HIV / Síndrome da Imunodeficiência Adquirida / Fármacos Anti-HIV / Profilaxia Pré-Exposição / Minorias Sexuais e de Gênero / COVID-19 Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: America do norte Idioma: En Revista: PLoS One Ano de publicação: 2023 Tipo de documento: Article